Specify a stock or a cryptocurrency in the search bar to get a summary
Mural Oncology plc
MURAMural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland. Address: 10 Earlsfort Terrace, Dublin, Ireland, D02 T380
Analytics
WallStreet Target Price
16.33 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures MURA
Dividend Analytics MURA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MURA
Stock Valuation MURA
Financials MURA
Results | 2019 | Dynamics |